Influence of TP53 Gene Mutations and its Allelic Status in Myelodysplastic Syndromes with Isolated 5q Deletion.
Maria Julia MontoroLaura PalomoClaudia HaferlachPamela AchaOnyee ChanVíctor NavarroYasuo KubotaFelicitas Isabel SchulzManja MeggendorferRobert BriskiNajla Al-AliBlanca XicoyFelix LopezFrancesc BoschTeresa GonzálezLea Naomi EderAndrés JerezYu-Hung Hung WangAlessia CampagnaValeria SantiniTeresa Bernal Del CastilloEsperanza SuchHwei-Fang TienNicolás Díaz VarelaUwe PlatzbeckerDetlef Thomas HaaseMaria Diez CampeloMatteo Giovanni Della PortaGuillermo Garcia-ManeroDaniel Howard WisemanUlrich GermingJaroslaw P MaciejewskiRami S KomrokjiFrancisco SoléTorsten HaferlachDavid ValcárcelPublished in: Blood (2024)
Mutations in the TP53 gene, particularly multihit alterations, have been associated with unfavorable clinical features and prognosis in patients diagnosed with myelodysplastic syndrome (MDS). Despite this, the role of TP53 gene aberrations in MDS with isolated deletion of chromosome 5 [MDS-del(5q)] remains unclear. This study aimed to assess the impact of TP53 gene mutations and their allelic state in patients with MDS-del(5q). To that end, a comprehensive analysis of TP53 abnormalities, examining both TP53 mutations and allelic imbalances, in 682 patients diagnosed with MDS-del(5q) was conducted. Twenty-four percent of TP53-mutated patients exhibited multihit alterations, while the remaining patients displayed monoallelic mutations. TP53 multihit alterations were predictive of an increased risk of leukemic transformation. The impact of monoallelic alterations was dependent on the variant allele frequency (VAF); patients with TP53 monoallelic mutations and VAF <20% exhibited behavior similar to TP53 wild type, and those with TP53 monoallelic mutations and VAF ≥20% presented outcomes equivalent to TP53 multihit patients. This study underscores the importance of considering TP53 allelic state and VAF in the risk stratification and treatment decision-making process for patients with MDS-del(5q).